Search results for: Kevin C. Maki

Items from 1 to 20 out of 84 results

article

Fibre and micronutrient intakes among fruit juice consumers and non‐consumers in the UK and France: Modelling the effects of consumption of an orange pomace juice product

Mary R. Dicklin, Rebecca Barron, Shellen Goltz, Janet Warren, more

Journal of Human Nutrition and Dietetics > 35 > 6 > 1230 - 1244

Background Fruit intake, including consumption of 100% fruit juice, is generally associated with a better diet quality and overall health. However, fruit and vegetable intakes are below recommendations in many countries. Methods The present study examined fruit juice intake and total energy and nutrient intakes according to juice consumption or non‐consumption in participants in the National Dietary...

article

Assessing Cardiovascular Disease Risk and Responses to Preventive Therapies in Clinical Practice

Kevin C. Maki, Mary R. Dicklin

Current Atherosclerosis Reports > 2018 > 20 > 5 > 1-10

Purpose of Review The aims of this review are to provide perspective on evaluation of relative and absolute cardiovascular disease (CVD) risk reductions for assessing the efficacy of preventive therapies and to summarize methods for evaluation of CVD risk in clinical practice. Recent Findings Major CVD risk factors can be used to stratify patients into risk categories. Results from recent trials...

article

Effects of n-3 fatty acid treatment on monocyte phenotypes in humans with hypertriglyceridemia

Xiao-Yuan Dai Perrard, Zeqin Lian, George Bobotas, Mary R. Dicklin, more

Journal of Clinical Lipidology > 2017 > 11 > 6 > 1361-1371

Hypertriglyceridemia increases risk for atherosclerotic cardiovascular disease and may contribute to atherosclerosis by changing circulating monocyte phenotypes. High-dose n-3 polyunsaturated fatty acids reduce blood triglyceride levels. Effects of triglyceride-lowering therapy on monocyte phenotypes are not well known.We examined effects of n-3 polyunsaturated fatty acid treatments (eicosapentaenoic...

article

Use of supplemental long-chain omega-3 fatty acids and risk for cardiac death: An updated meta-analysis and review of research gaps

Kevin C. Maki, Orsolya M. Palacios, Marjorie Bell, Peter P. Toth

Journal of Clinical Lipidology > 2017 > 11 > 5 > 1152-1160.e2

Randomized controlled trials (RCTs) assessing use of long-chain omega-3 polyunsaturated fatty acids (LC-OM3), primarily eicosapentaenoic acid, and/or docosahexaenoic acid have shown mixed results.The objectives of the study were to update and further explore the available RCT data regarding LC-OM3 supplementation and risk for cardiac death and to propose testable hypotheses for the mixed results obtained...

article

Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National Lipid Association

Jerome D. Cohen, Mark J. Cziraky, Terry A. Jacobson, Kevin C. Maki, more

Journal of Clinical Lipidology > 2017 > 11 > 4 > 891-900

Statin therapy is recommended for reducing atherosclerotic cardiovascular disease (ASCVD) risk. Significant risk can remain because of insufficient clinical response or statin intolerance. Proprotein convertase subtilisin/kexin type-9 (PCSK9) therapy lowers low-density lipoprotein cholesterol and has recently been shown to lower ASCVD events.The aim of the study was to assess the barriers and challenges...

article

Bioequivalence Demonstration for Ω-3 Acid Ethyl Ester Formulations: Rationale for Modification of Current Guidance

Kevin C. Maki, Colleen Johns, William S. Harris, Mark Puder, more

Clinical Therapeutics > 2017 > 39 > 3 > 652-658

The US Food and Drug Administration (FDA) draft guidance for establishing bioequivalence (BE) of ω-3 acid ethyl esters (containing both eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA] as ethyl esters), used to treat severe hypertriglyceridemia, recommends the conduct of 2 studies: one with participants in the fasting state and one with participants in the fed state. For the fasting study,...

article

A Novel ω-3 Acid Ethyl Ester Formulation Incorporating Advanced Lipid TechnologiesTM (ALT®) Improves Docosahexaenoic Acid and Eicosapentaenoic Acid Bioavailability Compared with Lovaza®

Miguel A. Lopez-Toledano, Thorsteinn Thorsteinsson, Ahmed Daak, Kevin C. Maki, more

Clinical Therapeutics > 2017 > 39 > 3 > 581-591

The US Food and Drug Administration has approved several highly purified ω-3 fatty acid prescription drugs for the treatment of severe hypertriglyceridemia. These differ in the amounts and forms of docosahexaenoic acid (DHA) and/or eicosapentaenoic acid (EPA). This study compared the bioavailability of SC401 (1530 mg EPA-ethyl esters [EEs] and DHA-EEs plus Advanced Lipid Technologies^⁎*Trademark: Advanced...

article

Minimal food effect for eicosapentaenoic acid and docosahexaenoic acid bioavailability from omega-3–acid ethyl esters with an Advanced Lipid TechnologiesTM (ALT®)–based formulation

Miguel A. Lopez-Toledano, Thorsteinn Thorsteinsson, Ahmed A. Daak, Kevin C. Maki, more

Journal of Clinical Lipidology > 2017 > 11 > 2 > 394-405

The absorption of eicosapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic acid (DHA; 22:6n-3) omega-3–acid ethyl esters (EEs) is influenced by food. There is a need for a formulation of EE that is less impacted by food effect. SC401 is a novel Advanced Lipid Technologies–based formulation of EPA-EE and DHA-EE. In the presence of an aqueous medium, Advanced Lipid Technologies forms stable micelles...

article

Effects of MAT9001 containing eicosapentaenoic acid and docosapentaenoic acid, compared to eicosapentaenoic acid ethyl esters, on triglycerides, lipoprotein cholesterol, and related variables

Kevin C. Maki, George Bobotas, Mary R. Dicklin, Margie Huebner, more

Journal of Clinical Lipidology > 2017 > 11 > 1 > 102-109

Long-chain omega-3 fatty acid concentrate pharmaceuticals are used in the United States for treatment of severe hypertriglyceridemia (≥500 mg/dL) and are under investigation as adjuncts to statins for lowering cardiovascular risk in patients with high triglycerides (TGs; 200–499 mg/dL).To evaluate MAT9001, an investigational prescription-only omega-3 fatty acid agent containing predominantly eicosapentaenoic...

article

Bioavailability of long chain omega-3 polyunsaturated fatty acids from phospholipid-rich herring roe oil in men and women with mildly elevated triacylglycerols

Chad M. Cook, Hogne Hallaråker, Per Christian Sæbø, Sheila M. Innis, more

Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA) > 2016 > 111 > C > 17-24

This randomized, single-blind, crossover trial assessed the bioavailability of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and docosapentaenoic acid (DPA) from two different sources, each examined over a 12h period following consumption of a single serving and after 2-weeks of daily supplementation. Thirty-two adults with fasting triacylglycerol (TAG) concentrations between 100 and 399mg/dL...

article

Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia

Kevin C. Maki, John R. Guyton, Carl E. Orringer, Ian Hamilton-Craig, more

Journal of Clinical Lipidology > 2016 > 10 > 4 > 905-914

Cardiovascular outcomes trials of fibrates, niacin, or omega-3 fatty acids alone, or added to a statin, have not consistently demonstrated reduced risk, but larger, statistically significant clinical benefits have been reported in subgroups with elevated triglycerides (TG) and/or elevated TG plus low high-density lipoprotein cholesterol (HDL-C).To perform a meta-analysis of the effects of therapies...

article

Metabolic syndrome is associated with muscle symptoms among statin users

Eliot A. Brinton, Kevin C. Maki, Terry A. Jacobson, Craig A. Sponseller, more

Journal of Clinical Lipidology > 2016 > 10 > 4 > 1022-1029

Muscle symptoms have been associated with statin use, but the relationship of statin-associated muscle symptoms with metabolic syndrome (MS) has not been reported previously.To evaluate the relationships between MS and its individual components with statin-associated muscle symptoms.Data were analyzed from the Understanding Statin Use in America and Gaps in Education (USAGE) study. Modified criteria...

article

Gender differences in side effects and attitudes regarding statin use in the Understanding Statin Use in America and Gaps in Patient Education (USAGE) study

Dean G. Karalis, Robert A. Wild, Kevin C. Maki, Ray Gaskins, more

Journal of Clinical Lipidology > 2016 > 10 > 4 > 833-841

Statin therapy has been shown to reduce cardiovascular morbidity and mortality, and the benefits of statin therapy are similar for men and women. Recent studies have shown that women are less likely to be treated with statin therapy, to be on higher doses of more potent statins, and to achieve their lipid goals as compared with men.To analyze results from the Understanding Statin Use in America and...

article

Effects of Eicosapentaenoic Acid Plus Docosapentaenoic Acid and Eicosapentaenoic Acid Alone on Fasting and Postprandial Lipids

Kevin C. Maki, William Keane, George Bobotas, Huaizhu Wu, more

Journal of Clinical Lipidology > 2016 > 10 > 3 > 700

article

Conducting omega-3 clinical trials with cardiovascular outcomes: Proceedings of a workshop held at ISSFAL 2014

Harry B. Rice, Aldo Bernasconi, Kevin C. Maki, William S. Harris, more

Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA) > 2016 > 107 > C > 30-42

In contrast to earlier long-chain (LC) omega-3 (i.e. EPA and DHA) investigations, some recent studies have not demonstrated significant effects of EPA and DHA on cardiovascular disease (CVD) outcomes. The neutral findings may have been due to experimental design issues, such as: maintenance on aggressive cardiovascular drug treatment overshadowing the benefits of LC omega-3s, high background LC omega-3...

chapter

Cardiovascular Epidemiology and Characterization of Atherosclerotic Disease Risk Factors

Kevin C. Maki, Martyn R. Rubin

Contemporary Cardiology > Comprehensive Cardiovascular Medicine in the Primary Care Setting > Cardiovascular Disease Risk Factors > 3-24

Over 80 million people in the United States exhibit one or more forms of cardiovascular disease (CVD), and atherosclerotic CVD (mainly coronary heart disease and stroke) is, by far, the leading cause of death among men and women. More women die from CVD in the United States each year than men. Atherosclerotic CVD has become a worldwide pandemic. While CVD mortality has declined over the last several...

article

National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2

Terry A. Jacobson, Kevin C. Maki, Carl E. Orringer, Peter H. Jones, more

Journal of Clinical Lipidology > 2015 > 9 > 6 Supplement > S1-S122.e1

An Expert Panel convened by the National Lipid Association previously developed a consensus set of recommendations for the patient-centered management of dyslipidemia in clinical medicine (part 1). These were guided by the principle that reducing elevated levels of atherogenic cholesterol (non–high-density lipoprotein cholesterol and low-density lipoprotein cholesterol) reduces the risk for atherosclerotic...

article

Triglyceride-Lowering Therapies Reduce Cardiovascular Disease Event Risk in Subjects with Hypertriglyceridemia

Kevin C. Maki, Michael H. Davidson, John R. Guyton, Carl E. Orringer, more

Journal of Clinical Lipidology > 2015 > 9 > 3 > 431

article

Statin Associated Muscle Symptoms: Characteristics of Patients and Recommendations by Providers*

Abdullah Khan, Kevin C. Maki, Matthew K. Ito, Jerome D. Cohen, more

Journal of Clinical Lipidology > 2015 > 9 > 3 > 460

article

National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report

Terry A. Jacobson, Matthew K. Ito, Kevin C. Maki, Carl E. Orringer, more

Journal of Clinical Lipidology > 2015 > 9 > 2 > 129-169

The leadership of the National Lipid Association convened an Expert Panel to develop a consensus set of recommendations for patient-centered management of dyslipidemia in clinical medicine. An Executive Summary of those recommendations was previously published. This document provides support for the recommendations outlined in the Executive Summary. The major conclusions include (1) an elevated level...

Publication date

Last 3 years (1)

Close

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

From:

To:
Set your own date range

INFONA - science communication portal

Search results for: Kevin C. Maki

Fibre and micronutrient intakes among fruit juice consumers and non‐consumers in the UK and France: Modelling the effects of consumption of an orange pomace juice product

Assessing Cardiovascular Disease Risk and Responses to Preventive Therapies in Clinical Practice

Effects of n-3 fatty acid treatment on monocyte phenotypes in humans with hypertriglyceridemia

Use of supplemental long-chain omega-3 fatty acids and risk for cardiac death: An updated meta-analysis and review of research gaps

Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National Lipid Association

Bioequivalence Demonstration for Ω-3 Acid Ethyl Ester Formulations: Rationale for Modification of Current Guidance

A Novel ω-3 Acid Ethyl Ester Formulation Incorporating Advanced Lipid TechnologiesTM (ALT®) Improves Docosahexaenoic Acid and Eicosapentaenoic Acid Bioavailability Compared with Lovaza®

Minimal food effect for eicosapentaenoic acid and docosahexaenoic acid bioavailability from omega-3–acid ethyl esters with an Advanced Lipid TechnologiesTM (ALT®)–based formulation

Effects of MAT9001 containing eicosapentaenoic acid and docosapentaenoic acid, compared to eicosapentaenoic acid ethyl esters, on triglycerides, lipoprotein cholesterol, and related variables

Bioavailability of long chain omega-3 polyunsaturated fatty acids from phospholipid-rich herring roe oil in men and women with mildly elevated triacylglycerols

Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia

Metabolic syndrome is associated with muscle symptoms among statin users

Gender differences in side effects and attitudes regarding statin use in the Understanding Statin Use in America and Gaps in Patient Education (USAGE) study

Effects of Eicosapentaenoic Acid Plus Docosapentaenoic Acid and Eicosapentaenoic Acid Alone on Fasting and Postprandial Lipids

Conducting omega-3 clinical trials with cardiovascular outcomes: Proceedings of a workshop held at ISSFAL 2014

Cardiovascular Epidemiology and Characterization of Atherosclerotic Disease Risk Factors

National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2

Triglyceride-Lowering Therapies Reduce Cardiovascular Disease Event Risk in Subjects with Hypertriglyceridemia

Statin Associated Muscle Symptoms: Characteristics of Patients and Recommendations by Providers*

National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report

Filter options

Publication date

Content availability

Publication type

Keywords

Data set

Journal

INFONA - science communication portal

Search results for: Kevin C. Maki

Add recipient

Sending message cancelled

Are you sure you want to cancel sending this message?

Send message

Filter options

Publication date

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

Content availability

Publication type

Keywords

Data set

Journal

Reporting an error / abuse

Sending the report failed

Accessibility options